{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:52:09Z","timestamp":1785909129519,"version":"3.56.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence regarding mirabegron-containing treatment for children with non-monosymptomatic nocturnal enuresis (NMNE) is limited, and its independent effects require controlled evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe exploratory clinical and urodynamic changes observed after mirabegron-containing multimodal treatment in children with NMNE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 31 children with NMNE who received mirabegron-containing treatment at the outpatient clinic of West China Hospital of Sichuan University between July 2024 and March 2025. Mirabegron was added to first-line treatment when voiding diaries suggested reduced functional bladder capacity. Patients received 25 or 50\u2005mg once nightly according to age and weight for 12 weeks, without dose adjustment. Voiding diary parameters and available urodynamic measurements were compared before and after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 12 weeks, voiding frequency, daytime incontinence episodes, and nocturnal enuresis episodes decreased, while maximum voided volume increased. Maximum cystometric capacity was measured before and after treatment in all 31 patients and showed a modest within-cohort increase. Follow-up measurements of detrusor pressure at the end of filling and bladder compliance were available for only four patients. These descriptive data showed lower detrusor pressure and higher bladder compliance after treatment. Based on nocturnal enuresis episode reduction, 28 of 31 patients (90.3%) met the predefined diary-based improvement threshold. This proportion cannot be interpreted as a pharmacologic response attributable to mirabegron because treatment was multimodal and uncontrolled. No treatment-related adverse events were documented, but retrospective records are insufficient to establish safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mirabegron-containing multimodal treatment was associated with within-cohort changes in voiding diary parameters and a modest increase in maximum cystometric capacity. The retrospective, single-arm design precludes causal or treatment-specific inference, and patient-centered outcomes were not assessed. These findings are preliminary, exploratory, and hypothesis-generating rather than practice-informing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1866454","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:38:50Z","timestamp":1785908330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory clinical and urodynamic changes associated with mirabegron-containing multimodal treatment in children with non-monosymptomatic nocturnal enuresis: a retrospective real-world study"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhenxian","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xizang University (The Second People's Hospital of Xizang Autonomous Region)","place":["Lhasa, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangcun","family":"Silang","sequence":"additional","affiliation":[{"name":"Department of Urology, People\u2019s Hospital of Xizang Autonomous Region","place":["Lhasa, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunzhu","family":"Gesang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital of Xizang University (The Second People's Hospital of Xizang Autonomous Region)","place":["Lhasa, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jpurol.2019.12.020","article-title":"Management and treatment of nocturnal enuresis: an updated standardization document from the international children\u2019s continence society","volume":"16","author":"Nev\u00e9us","year":"2020","journal-title":"J Pediatr Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jpurol.2012.10.026","article-title":"International children\u2019s continence society. Evaluation and treatment of nonmonosymptomatic nocturnal enuresis: a standardization document from the international children\u2019s continence society","volume":"9","author":"Franco","year":"2013","journal-title":"J Pediatr Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/nau.22751","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the international children\u2019s continence society","volume":"35","author":"Austin","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"B4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/pch\/pxad023","article-title":"Evaluation and management of enuresis in the general paediatric setting","volume":"28","author":"Harris","year":"2023","journal-title":"Paediatr Child Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"31.e1","DOI":"10.1016\/j.jpurol.2019.10.009","article-title":"The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation","volume":"16","author":"Rittig","year":"2020","journal-title":"J Pediatr Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40272-021-00452-4","article-title":"Mirabegron: pediatric first approval","volume":"23","author":"Keam","year":"2021","journal-title":"Paediatr Drugs"},{"key":"B7","volume-title":"MYRBETRIQ (Mirabegron Extended-Release Tablets) and MYRBETRIQ Granules (Mirabegron for Extended-Release Oral Suspension): Prescribing Information","year":"2021"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/nau.24657","article-title":"Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: an open-label, phase 3, dose-titration study","volume":"40","author":"Baka-Ostrowska","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"B9","doi-asserted-by":"publisher","first-page":"655.e1","DOI":"10.1016\/j.jpurol.2020.07.020","article-title":"Efficacy and safety of mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction","volume":"16","author":"Sager","year":"2020","journal-title":"J Pediatr Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4111\/icu.20200380","article-title":"Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: a preliminary study","volume":"62","author":"Kim","year":"2021","journal-title":"Investig Clin Urol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/JU.0000000000002361","article-title":"\u03b23-adrenoceptor agonist for the treatment of bladder dysfunction in children: a systematic review and meta-analysis","volume":"207","author":"Kim","year":"2022","journal-title":"J Urol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"801517","DOI":"10.3389\/fped.2021.801517","article-title":"Mirabegron in overactive bladder and its role in exit strategy after botulinum toxin treatment in children","volume":"9","author":"Tan","year":"2022","journal-title":"Front Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jpurol.2023.08.015","article-title":"Long-term beneficial effects of mirabegron in pediatric patients with therapy-refractory neurogenic lower urinary tract dysfunction","volume":"19","author":"van Veen","year":"2023","journal-title":"J Pediatr Urol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","article-title":"Prospective pilot study of mirabegron in pediatric patients with overactive bladder","volume":"70","author":"Blais","year":"2016","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5173\/ceju.2023.237","article-title":"Safety and effectiveness of mirabegron for children and adolescents with refractory idiopathic overactive bladder for improving urinary symptoms: a systematic review","volume":"77","author":"Franco-Buenaventura","year":"2024","journal-title":"Cent European J Urol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1866454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:38:51Z","timestamp":1785908331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1866454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":15,"alternative-id":["10.3389\/fped.2026.1866454"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1866454","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1866454"}}